Clinical effects of high oral dose of donepezil for patients with Alzheimer's disease in Japan
Authors: NOZAWA, Motohiro; ICHIMIYA, Yosuke1; NOZAWA, Eiko2; UTUMI, Yushi1; SUGIYAMA, Hideki1; MURAYAMA, Norio1; ISEKI, Eizo1; ARAI, Heii2
Source: Psychogeriatrics, Volume 9, Number 2, June 2009 , pp. 50-55(6)
Publisher: Blackwell Publishing
Abstract:
Background: Donepezil 10 mg/day gained approval in Japan in August 2007 for the treatment of cognitive dysfunction in advanced Alzheimer's disease. Methods: We evaluated the efficacy and adverse effects of donepezil when the dose was increased to 10 mg/day in 61 Japanese patients with Alzheimer's disease. Cognitive function was evaluated using the Revised Hasegawa Dementia Scale and mini-mental state examination at the day before starting, and at 4, 8 and 24 weeks after starting donepezil 10 mg/day. The relationship with apolipoprotein E4 was also investigated. Results: The Revised Hasegawa Dementia Scale and mini-mental state examination scores were not statistically significantly different at any time after starting donepezil 10 mg/day. It can be anticipated that donepezil 10 mg/day will especially inhibit deterioration of cognitive function in advanced Alzheimer's disease. The incidence of adverse events was 11.5%, lower than the rate of 40% or higher recorded during previous clinical trials. Conclusions: The progression of cognitive dysfunction could be inhibited by increasing the dose of donepezil to 10 mg/day. It was suggested that longer-term treatment with 5 mg/day might lead to fewer adverse events when the dose is increased to 10 mg/day.Keywords: Alzheimer's disease; apolipoprotein E4; dementia; donepezil; high oral dose
Document Type: Research article
DOI: 10.1111/j.1479-8301.2009.00291.x
Affiliations: 1: Department of Psychiatry, Juntendo Tokyo Koto Geriatric Medial Center, Juntendo University School of Medicine, and 2: Department of Psychiatry, Juntendo University School of Medicine, Tokyo, Japan

Click here for Page Help